Actrapid

Insulin Human, the active ingredient in Actrapid, is a recombinant human insulin presented as a 100 IU/mL solution for subcutaneous or intravenous use. It is used to manage blood glucose levels in patients with diabetes mellitus, including type 1 and type 2 diabetes, as well as diabetic ketoacidosis and hyperglycemia. GNH USA supplies Actrapid as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Actrapid is a rapid-acting insulin analog designed to mimic the natural insulin response in the body, helping to regulate glucose uptake and inhibit hepatic glucose production. This makes it a crucial component in the management of diabetes, ensuring patients maintain stable blood sugar levels.

Actrapid is primarily used in the management of diabetes mellitus, acting on the insulin pathway to regulate blood glucose levels. It is indicated for the following conditions:

- Type 1 diabetes mellitus: Manages blood glucose levels in patients who require insulin due to insufficient insulin production. - Type 2 diabetes mellitus: Used in conjunction with diet and exercise to improve glycemic control in patients who do not respond adequately to oral hypoglycemic agents. - Diabetic ketoacidosis: Helps to rapidly lower blood glucose levels and correct metabolic acidosis in severe cases. - Hyperglycemia: Used to manage high blood glucose levels in various clinical settings.

Actrapid, like other insulin therapies, can cause a range of side effects, which can be categorized as common or serious.

Common Side Effects: - Hypoglycemia: Low blood sugar levels, which can cause symptoms such as sweating, dizziness, and confusion. - Injection site reactions: Redness, swelling, or itching at the site of injection. - Weight gain: Due to the anabolic effects of insulin, leading to increased fat storage. - Lipodystrophy: Changes in fat distribution at the injection sites, which can affect insulin absorption.

Serious or Rare Side Effects: - Severe hypoglycemia: Can lead to loss of consciousness or seizures if blood sugar levels drop too low. - Hypokalemia: Low potassium levels in the blood, which can cause muscle weakness and irregular heartbeats. - Allergic reactions: Rare but can be severe, including anaphylaxis, which requires immediate medical attention. - Fluid retention: Can lead to edema, particularly in patients with heart or kidney conditions.

Actrapid should be used with caution and under medical supervision to ensure safe and effective treatment. Important precautions include:

- Hypoglycemia management: Regular monitoring of blood glucose levels is essential to prevent hypoglycemia, especially in patients who are physically active or have irregular eating habits. - Dose adjustment: The dosage should be adjusted based on individual patient needs, considering factors such as diet, exercise, and other medications. - Hypokalemia risk: Patients should be monitored for low potassium levels, particularly during the initial phases of treatment. - Allergic reactions: Patients with a history of insulin allergies should be closely monitored for signs of allergic reactions. - Fluid retention: Patients with heart or kidney conditions should be monitored for signs of fluid retention and edema. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Actrapid can interact with various medications, which can affect its efficacy and safety. These interactions can be categorized as major or moderate.

Major Interactions (Avoid): - Oral hypoglycemic agents: Concurrent use can increase the risk of severe hypoglycemia, requiring careful monitoring and dose adjustment. - Beta-blockers: Can mask the symptoms of hypoglycemia, making it difficult to recognize and manage low blood sugar levels. - Corticosteroids: Can reduce the effectiveness of insulin, requiring dose adjustments to maintain glycemic control.

Moderate Interactions (Monitor Closely): - ACE inhibitors: May increase the risk of hypoglycemia, requiring close monitoring of blood glucose levels. - Angiotensin II receptor blockers: Can also increase the risk of hypoglycemia, necessitating careful monitoring. - Thiazide diuretics: Can reduce the effectiveness of insulin, requiring dose adjustments to maintain glycemic control.